| 摘要 |
The disclosure relates to novel 11.beta.-hydroxy prostaglandin analogues, for example 16-(3-chlorophenoxy)-9.alpha.,11.beta.,15.alpha.-trihydroxy-17,18,19-20-tetranor-5-cis,13-trans-prostadienoic acid, to processes for their manufacture and pharmaceutical or veterinary compositions containing them, and to a method of inducing luteolysis in an animal bost, using the novel 11.beta.-hydroxy prostaglandin analogues. |
